Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes

家族性和遗传性癌症综合征的临床遗传学研究

基本信息

项目摘要

The Clinical Genetics Branch (CGB) is NCI's base for intramural clinical cancer genetics translational research activity. CGB brings a multidisciplinary, epidemiologic perspective to: Understanding the role of genes in the cause, treatment, and prevention of cancer; Developing comprehensive management strategies for high-risk individuals and families; and Training the next generation of clinical cancer genetics investigators.Hereditary Breast/Ovarian Cancer (HBOC) is based on a prospective cohort of 33 BRCA mutation-positive families with extensive clinical/epidemiologic data and biological samples. Clinical activity related to this study has ended, but its biospecimens continue to be used in multiple translational research projects. The most recent analysis of breast cancer risk in these prospectively-monitored families indicates that mutation-negative women from these mutation-positive families have risks that are similar to those seen in the general population. To date, 20 clinical manuscripts have been published and 40 reports plus 8 manuscripts under review (in collaboration with the international consortium CIMBA) elucidating genetic modifiers of BRCA-related breast and ovarian cancer penetrance have been published. Inherited Bone Marrow Failure Syndromes (IBMFS) Study targets Fanconi anemia (FA) and related disorders which include high risk of aplastic anemia, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and selected solid tumors. We have enrolled 1722 members from 406 IBMFS families. Major findings include quantitative estimates of FA- and dyskeratosis congenita (DC)-related cancer risks, identifying the striking similarity in cancer risks in these 2 disorders, expanding the clinical phenotype of these syndromes, and identifying very short telomeres as pathognomonic for DC. Under a Fanconi Anemia Research Foundation grant, we are writing a report on immune function in FA patients. We collaborated on development of an in vitro assay for p
临床遗传学分支(CGB)是NCI研究壁内临床癌症的基础 遗传学转化研究活动。广发银行带来了多学科,流行病学 观点:了解基因在病因,治疗和预防中的作用 为高危个人和家庭制定综合管理战略; 培养下一代临床癌症遗传学研究人员。遗传学 乳腺癌/卵巢癌(HBOC)基于33例BRCA突变阳性患者的前瞻性队列, 具有大量临床/流行病学数据和生物样本的家庭。临床活性 与这项研究有关的研究已经结束,但其生物标本继续被用于多个 翻译研究项目。最新的乳腺癌风险分析显示, 前瞻性监测的家庭表明,来自这些家庭的突变阴性妇女, 突变阳性家庭的风险与一般家庭相似, 人口迄今为止,已发表20篇临床手稿,40份报告,加上8份 正在审查的手稿(与国际联合会CIMBA合作) 阐明BRCA相关的乳腺癌和卵巢癌的遗传修饰基因, 公开.针对范可尼贫血(FA)的遗传性骨髓衰竭综合征(IBMFS)研究 和相关疾病,包括高风险的再生障碍性贫血,骨髓增生异常综合征 (MDS)急性髓性白血病(AML)和选定的实体瘤。我们已经招募了1722名会员 来自406个IBMFS家庭。主要发现包括FA和角化不良的定量估计 先天性(DC)相关的癌症风险,确定癌症风险的惊人相似性, 这两种疾病,扩大这些综合征的临床表型,并确定非常 短端粒是DC的特征性表现。在范科尼贫血研究基金会的资助下,我们 正在写一份关于FA患者免疫功能的报告。我们合作开发了一种 害虫体外测定

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sharon A. Savage其他文献

Telomere length and cancer risk: finding Goldilocks
  • DOI:
    10.1007/s10522-023-10080-9
  • 发表时间:
    2023-12-18
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Sharon A. Savage
  • 通讯作者:
    Sharon A. Savage
Living with rare genetic disease during the COVID-19 pandemic: A qualitative study of adolescents and young adults with Li-Fraumeni Syndrome
COVID-19 大流行期间患有罕见遗传病:对患有 Li-Fraumeni 综合征的青少年和年轻人的定性研究
  • DOI:
    10.1016/j.rare.2024.100034
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Allison Werner;Payal P. Khincha;Ashley S. Thompson;C. Rising;Alix G Sleight;Catherine Wilsnack;Patrick Boyd;Alexandra E. Feldman;R. F. Shepherd;Sharon A. Savage
  • 通讯作者:
    Sharon A. Savage
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
骨肉瘤的种系和体细胞遗传学——连接病因学、生物学和治疗学
  • DOI:
    10.1038/nrendo.2017.16
  • 发表时间:
    2017-03-24
  • 期刊:
  • 影响因子:
    40.000
  • 作者:
    D. Matthew Gianferante;Lisa Mirabello;Sharon A. Savage
  • 通讯作者:
    Sharon A. Savage
Publication of Second Edition emTelomere Biology Disorders: Diagnosis and Management Guidelines/em
《端粒生物学紊乱:诊断和管理指南(第二版)》出版
  • DOI:
    10.1182/blood-2022-171040
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Katie Barrett Stevens;Hannah A. Raj;Heidi Carson;Sharon A. Savage;Suneet Agarwal
  • 通讯作者:
    Suneet Agarwal
Telomere Shortest Length Assay (TeSLA) Defines the Distribution and Accumulation of the Shortest Telomeres in Dyskeratosis Congenita
  • DOI:
    10.1182/blood-2022-168940
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Hannah A. Raj;Tsung-Po Lai;Marena R. Niewisch;Youjin Wang;Stephen R. Spellman;Abraham Aviv;Shahinaz M. Gadalla;Sharon A. Savage
  • 通讯作者:
    Sharon A. Savage

Sharon A. Savage的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sharon A. Savage', 18)}}的其他基金

Intervention Trials in Persons at Increased Genetic Risk of Cancer
针对癌症遗传风险增加人群的干预试验
  • 批准号:
    9549603
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Family Studies
家庭研究
  • 批准号:
    10007394
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes
家族性和遗传性癌症综合征的临床遗传学研究
  • 批准号:
    10702919
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Family Studies
家庭研究
  • 批准号:
    10702899
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Genetic Epidemiology of Telomere Maintenance and Cancer Etiology
端粒维持的遗传流行病学和癌症病因学
  • 批准号:
    8349586
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Epidemiology and Genetics of Susceptibility to COVID-19 Infection
COVID-19 感染易感性的流行病学和遗传学
  • 批准号:
    10702965
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Genetic Epidemiology of Telomere Maintenance and Cancer Etiology
端粒维持的遗传流行病学和癌症病因学
  • 批准号:
    7733744
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Intervention Trials in Persons at Increased Genetic Risk of Cancer
针对癌症遗传风险增加人群的干预试验
  • 批准号:
    10007416
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Genetic Epidemiology of Telomere Maintenance and Cancer Etiology
端粒维持的遗传流行病学和癌症病因学
  • 批准号:
    10007433
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Epidemiology and Genetics of Susceptibility to COVID-19 Infection
COVID-19 感染易感性的流行病学和遗传学
  • 批准号:
    10263793
  • 财政年份:
  • 资助金额:
    $ 1152.87万
  • 项目类别:

相似海外基金

Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 1152.87万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10722602
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10368246
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells
Eltombopag:对正常和再生障碍性贫血造血干细胞的新作用模式
  • 批准号:
    10676888
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10600143
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
  • 批准号:
    10347646
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10370775
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
  • 批准号:
    10545024
  • 财政年份:
    2022
  • 资助金额:
    $ 1152.87万
  • 项目类别:
Identification of autoantigens presented by specific HLA class I alleles in aplastic anemia
再生障碍性贫血中特定 HLA I 类等位基因呈现的自身抗原的鉴定
  • 批准号:
    19H03686
  • 财政年份:
    2019
  • 资助金额:
    $ 1152.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of novel genes related to aplastic anemia using mouse models.
使用小鼠模型对与再生障碍性贫血相关的新基因进行功能分析。
  • 批准号:
    19K08297
  • 财政年份:
    2019
  • 资助金额:
    $ 1152.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了